Moderna’s pivotal vaccine trial will evaluate, in 30,000 subjects across the U.S., whether two doses protects against symptomatic Covid-19
The pivotal trial will evaluate, in 30,000 subjects across the U.S., whether two doses prevents symptomatic Covid-19
It’s far from business as usual at the Indianapolis headquarters of Eli Lilly, with only a sixth of the pharma company’s employees working on-site to develop potential Covid-19 treatments. WSJ’s Peter Loftus takes us inside. Photo: Eli Lilly
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Doja Cat Had The Coronavirus After Saying 'I Don't Give A Fuck About Corona'In early March, the 'Say So' rapper had mocked people who were scared of the virus. She now says she experienced 'a four-day symptom freak out.'
Read more »
Moderna gets further $472 million U.S. award for coronavirus vaccine developmentModerna Inc said on Sunday it has received an additional $472 million from the U.S. government's Biomedical Advanced Research and Development Authority (BARDA) to support development of its novel coronavirus vaccine.
Read more »
Moderna gets further $472 million U.S. award for coronavirus vaccine developmentModerna said on Sunday it has received an additional $472 million from the U.S. government's Biomedical Advanced Research and Development Authority to support the development of its novel coronavirus vaccine.
Read more »
Hundreds jam airport as evacuations from Vietnam's Danang beginHundreds flooded the airport in the central Vietnamese tourism hotspot of Danang on Monday after three residents tested positive for the coronavirus and the evacuation of 80,000 people began.
Read more »
Moderna's COVID-19 vaccine candidate moves into late-stage trialModerna Inc said on Monday it has started a U.S. government-backed late-stage trial for its COVID-19 vaccine candidate, the first to be implemented under the Trump administration's Operation Warp Speed anti-coronavirus program.
Read more »